Molecular Targeting Therapy Against Promyelocytic Leukemia Protein Using Arsenic Acids in Experimental Intracranial Medulloblastoma

DOI Web Site PubMed 参考文献40件
  • GU Chunyu
    Department of Neurosurgery, Hamamatsu University School of Medicine Department of Neurosurgery, Shengjing Hospital of China Medical University
  • YOKOTA Naoki
    Department of Neurosurgery, Hamamatsu University School of Medicine Yokohama CyberKife Center
  • GAO Yun
    Department of Neurosurgery, Hamamatsu University School of Medicine
  • AMANO Shinji
    Department of Neurosurgery, Hamamatsu University School of Medicine
  • KOIZUMI Shinichiro
    Department of Neurosurgery, Hamamatsu University School of Medicine
  • TOKUYAMA Tsutomu
    Department of Neurosurgery, Hamamatsu University School of Medicine
  • NAMBA Hiroki
    Department of Neurosurgery, Hamamatsu University School of Medicine

この論文をさがす

抄録

Our previous study using human Daoy medulloblastoma cells showed that the promyelocytic leukemia (PML) gene was significantly upregulated (2.5-fold) in cells positive to prominin-1 antigen (CD133), a possible marker for cancer initiating cells. Arsenic trioxide (As2O3) is known to degrade PML protein and has been used for the treatment of patients with acute PML. In the present study, the effect of PML targeting therapy with As2O3 and cytarabine (Ara-C) on Daoy medulloblastoma cell proliferation was investigated. Daoy cells were pretreated with As2O3 for 6 weeks. The As2O3-pretreated Daoy cells were cultured in medium containing Ara-C and cell viability was examined. Next, the As2O3-pretreated Daoy cells were inoculated into the nude mouse brain and the effect of Ara-C on the tumor size was evaluated. A significant increase in chemosensitivity to Ara-C was observed in the As2O3-pretreated Daoy cells in both in vitro and in vivo conditions. PML and CCND1 (cyclin D1) protein expression of Daoy medulloblastoma cells was downregulated by As2O3 treatment. PML has been proposed as a novel therapeutic target to eradicate quiescent leukemia-initiating cells, and PML-expressing CD133-positive cells are similarly a potential therapeutic target of treatment for medulloblastoma.<br>

収録刊行物

参考文献 (40)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ